Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples